Service on the Data Monitoring Committee of the CPEP (Calcium for Pre-eclampsia Prevention) has led us to four conclusions about clinical trials which we should like to present to this gathering of biostatisticians for their reactions: (i) meta-analyses of the pertinent published trials of the same
ANALYSIS OF UNCONTROLLED TREATMENT CHANGES IN HIV CLINICAL TRIALS
β Scribed by HUNG-MO LIN; MICHAEL D. HUGHES
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 885 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
β¦ Synopsis
Some clinical trials involving subjects with the human immunodeficiency virus (HIV) allow a subject to change treatment when a marker of disease progression, for example, the CD4 cell count, falls below a defined threshold. Although the change does not involve a randomized control, there is considerable interest in assessing whether it might have beneficial effects on the marker levels. However, the effects of regression to the mean will confound a simple analysis of the repeated measurements obtained before and after the cross-over. In this paper, we present a likelihood-based methodology for this problem and apply it to assess a cross-over from placebo to treatment with a drug, zidovudine, in a cohort of HIV infected individuals. This cross-over occurred when a subject first had two successive CD4 cell counts below 500/mm3. As well as providing important information about the effects of introducing zidovudine among subjects with early asymptomatic HIV infection, this paper illustrates methods for verifying model assumptions, an important component of such analyses which are necessarily model dependent.
π SIMILAR VOLUMES
We consider clinical trials in which information is available about subjects' treatment changes after randomization. To understand whether any difference between randomized groups in the intention-to-treat analysis can be explained by such treatment changes, we need analysis strategies which take ac
The results of surgery for liver cancer (resection or transplantion) have so far been evaluated against older retrospective reports of the survival of series of patients left untreated. Even though it has been taken for granted that "surgical therapy offers the only chance of cure," the validity of
Exploration of the variation of treatment effect over time in randomized clinical trials with low event rates is limited by lack of power. A meta-analysis on individual patient data from such trials can partly solve the problem, but brings other computational difficulties. Using an example in hypert